Biogen Idec reports good results from latest Tysabri testing
Biogen Idec Inc.’s multiple sclerosis drug Tysabri performed well in recent studies that compared it to other treatments on the market, according to the Weston biotechnology company and its Irish partner in Tysabri, Elan Corporation plc.
In particular, the results showed patients taking the drug who contract a rare brain disease -- called progressive multifocal leukoencephalopathy -- have a much better chance of recovering if the condition is detected earlier.
Details from the studies will be presented at the 65th Annual Meeting of the American Academy of Neurology in San Diego.
“These new data reinforce our belief in the substantial efficacy Tysabri has demonstrated at both the early and advanced stages of relapsing forms of MS,” said Alfred Sandrock, Biogen Idec’s chief medical officer.